Literature DB >> 20840541

Epidemiology of invasive fungal infections in neonates and children.

W J Steinbach1.   

Abstract

Invasive fungal infections are major causes of morbidity and mortality in neonates and in both immunocompromised and immunocompetent children. Although these infections have been well characterized in adults, the incidence and analysis of risk factors, diagnostic tools, treatments and outcomes have not been well described for large cohorts of paediatric or neonatal patients. Paediatric exclusion has limited our knowledge of the epidemiology and pathophysiology of paediatric fungal disease, and has also resulted in a paucity of data regarding the safety and efficacy of paediatric antifungal therapy. Previous paediatric cooperative models in other disciplines have successfully advanced our understanding and treatments of childhood diseases, but in the past there has not been a similar organization for paediatric invasive fungal infections. Although there are numerous other reviews outlining the differences in paediatric antifungal dosing pharmacokinetics, there are only smaller epidemiological reports depicting the exact distribution and outcomes of paediatric invasive fungal infections treated with these antifungals. This review will highlight some of the available epidemiological data on paediatric invasive fungal infections.
© 2010 The Author Clinical Microbiology and Infection © 2010 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20840541     DOI: 10.1111/j.1469-0691.2010.03288.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  17 in total

1.  Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus.

Authors:  Theodouli Stergiopoulou; Joseph Meletiadis; Tin Sein; Paraskevi Papaioannidou; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

2.  Amphotericin B in Pediatrics: Analysis by Age Stratification Suggests a Greater Chance of Adverse Events from 13 Months of Age Onwards.

Authors:  Francelise Bridi Cavassin; João Luiz Baú-Carneiro; Fabio de Araújo Motta; Ana Paula Matzenbacher Ville; Leticia Staszczak; Flávio de Queiroz-Telles
Journal:  Paediatr Drugs       Date:  2022-07-18       Impact factor: 3.930

Review 3.  Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.

Authors:  Rajendra S Kadam; Johannes N Van Den Anker
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

Review 4.  Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice.

Authors:  Athanasios Tragiannidis; Charalampos Dokos; Thomas Lehrnbecher; Andreas H Groll
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

5.  Invasive fungal disease in PICU: epidemiology and risk factors.

Authors:  Olivier Brissaud; Julie Guichoux; Jerome Harambat; Olivier Tandonnet; Theoklis Zaoutis
Journal:  Ann Intensive Care       Date:  2012-02-22       Impact factor: 6.925

6.  Safety and Effectiveness of Micafungin in Japanese Pediatric Patients: Results of a Postmarketing Surveillance Study.

Authors:  Chie Kobayashi; Tomoko Hanadate; Toshiro Niwa; Takashi Yoshiyasu; Masahiro So; Keita Matsui
Journal:  J Pediatr Hematol Oncol       Date:  2015-07       Impact factor: 1.289

Review 7.  Epidemiology of Invasive Fungal Disease in Children.

Authors:  Zoi Dorothea Pana; Emmanuel Roilides; Adilia Warris; Andreas H Groll; Theoklis Zaoutis
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

8.  Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections.

Authors:  Nathan P Wiederhold; Lydia A Herrera
Journal:  Clin Med Insights Pediatr       Date:  2012-06-07

9.  Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan.

Authors:  Masaaki Mori
Journal:  J Infect Chemother       Date:  2013-06-04       Impact factor: 2.211

10.  Species-based comparison of disease severity and risk factors for disseminated Candida infections in pediatric patients.

Authors:  John J Hawkshead; Russell B Van Dyke; Susan E Hassig; Larry S Webber; Rodolfo E Begue
Journal:  Infect Drug Resist       Date:  2016-04-18       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.